论文部分内容阅读
1979年我随中华医学会代表团赴瑞典进行访问。访问期间,就该国新药研究方面的情况进行了了解,现简介如下。新药的研究与发展瑞典的新药研究工作主要在药厂和医院进行。各药厂用于新药研究与发展的经费一般为总经费的15%,个别药厂有高达20%的。该国所用药物的一半为自产,一半为进口。生产的药物,25%用于国内,75%出口。新药研究的面比较广,重点是心血管系统药和抗恶性肿瘤药。研究的起点比较高,研究新药基本上以胜过老药,能进入国际市场为目标。Kabi 药厂研究静脉营养液已有十几年历史,从单纯的氨基酸和糖的营养液到应用脂肪乳剂、各种维生素和旷物质作营养液,现已能配成用五、六十种营
In 1979, I accompanied a delegation of Chinese Medical Association to Sweden for a visit. During his visit, he learned about the new drug research in the country. The briefing is as follows. Research and Development of New Drugs New drug research in Sweden is mainly carried out in pharmaceutical factories and hospitals. The funds used for the research and development of new drugs at the pharmaceutical companies are generally 15% of the total funding and as many as 20% at individual pharmaceutical companies. Half of the medicines used in the country are self-produced and half are imported. Drugs produced, 25% for domestic use and 75% for export. New drug research is more broad, focusing on cardiovascular system drugs and anti-cancer drugs. The starting point of the study is relatively high, and research on new drugs basically aims to be better than the old drugs and enter the international market. Kabi Pharmaceutical Research intravenous nutrient solution has more than 10 years of history, from a simple amino acid and sugar nutrient solution to the application of fat emulsion, a variety of vitamins and minerals as nutrient solution, has been able to match with five or sixty camps